HILLEVAX INC. - COMMO

HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

07 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire

HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

08 авг 2024 19:20:24 Источник Nasdaq GlobeNewswire

HilleVax Announces Reduction in Force

31 июл 2024 16:00:00 Источник Nasdaq GlobeNewswire

HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants

08 июл 2024 07:30:00 Источник Nasdaq GlobeNewswire

HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

09 май 2024 16:05:00 Источник Nasdaq GlobeNewswire

HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress

20 мар 2024 16:00:00 Источник Nasdaq GlobeNewswire

HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer

18 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire

HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China

08 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire

HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 янв 2024 18:28:04 Источник Nasdaq GlobeNewswire

HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

09 ноя 2023 16:05:01 Источник Nasdaq GlobeNewswire

HilleVax to Present at Upcoming Investor Conferences

01 ноя 2023 16:48:37 Источник Nasdaq GlobeNewswire

HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

26 сен 2023 16:01:00 Источник Nasdaq GlobeNewswire

HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

25 сен 2023 07:00:00 Источник Nasdaq GlobeNewswire

HilleVax Announces Pricing of Public Offering of Common Stock

19 сен 2023 20:05:50 Источник Nasdaq GlobeNewswire

HilleVax Announces Proposed Public Offering of Common Stock

19 сен 2023 16:09:25 Источник Nasdaq GlobeNewswire

HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

14 авг 2023 07:00:01 Источник Nasdaq GlobeNewswire

HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

12 май 2023 16:05:00 Источник Nasdaq GlobeNewswire

HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors

09 май 2023 07:00:01 Источник Nasdaq GlobeNewswire

HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate

25 апр 2023 06:45:00 Источник Nasdaq GlobeNewswire

HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress

17 мар 2023 16:05:00 Источник Nasdaq GlobeNewswire